Genentech Announces Promising Phase III Results for Vamikibart in Treating Uveitic Macular Edema

Genentech, a member of the Roche Group, has unveiled results from two pivotal Phase III trials—MEERKAT and SANDCAT—evaluating the investigational drug vamikibart for uveitic macular edema (UME), a sight-threatening complication…

Continue Reading Genentech Announces Promising Phase III Results for Vamikibart in Treating Uveitic Macular Edema
License Territory Expanded: ARVN001 for UME
source: pixabay.com

License Territory Expanded: ARVN001 for UME

When it comes to pharmaceuticals, licensed territory helps ensure that drugs within a certain territory are offered to patients. Exclusive licenses sometimes mean that pharmaceuticals are only available in specific…

Continue Reading License Territory Expanded: ARVN001 for UME